Ribas Antoni
Division of Hematology-Oncology, Department of Medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA.
Methods Mol Biol. 2014;1102:3-9. doi: 10.1007/978-1-62703-727-3_1.
Melanoma is a main example of how applying advances in basic biology, pharmacology, and molecular diagnostics into the clinic results in unprecedented benefits to patients. After many years of lack of advances in the treatment of patients with metastatic melanoma, the advent of new therapies that block driver oncogenic signaling and modulate immune responses to cancer provided the first studies with a positive impact in overall survival (OS) of patients with advanced melanoma. The pace of progress in the treatment of this disease has been greatly accelerated by these initial breakthroughs, and it continues with new generation agents and combinatorial approaches.
黑色素瘤是一个典型例子,展示了将基础生物学、药理学和分子诊断学的进展应用于临床如何给患者带来前所未有的益处。在转移性黑色素瘤患者的治疗多年没有进展之后,阻断驱动致癌信号并调节对癌症的免疫反应的新疗法的出现,首次使晚期黑色素瘤患者的总生存期(OS)研究产生了积极影响。这些初步突破极大地加速了这种疾病的治疗进展速度,并且新一代药物和联合治疗方法仍在继续推动这一进程。